New COVID Variant PJ.2.1 Spreads Across Countries as WHO Warns Its Symptoms Mimic a Cold

A new lineage of the virus that causes COVID-19 is turning up in more and more countries, and it is doing so quietly. The variant is called PJ.2.1. It was first spotted in a sample taken in Ontario, Canada, on May 2, 2026, and in the months since it has been detected across North America, Europe, Asia and Oceania. In Ontario it now accounts for about a quarter of the coronavirus samples that scientists have sequenced. The World Health Organization has said it is watching the variant closely, and on November 8 it warned that the symptoms it causes can look so much like a common cold or seasonal flu that symptoms alone cannot reliably tell the infections apart. At the same time, the evidence so far gives no sign that PJ.2.1 makes people more seriously ill than earlier variants. That combination — a variant that spreads well but has not shown greater severity — is the story of this week in COVID variant PJ.2.1 symptoms spread November 2026.

1. What PJ.2.1 Is and Where It Came From

PJ.2.1 is a lineage of SARS-CoV-2, the coronavirus behind COVID-19. It is not a new virus, and it is not a separate disease. It is a branch of the same family tree that has produced every variant since the pandemic began, and its interest to scientists comes from how quickly it appeared and how many changes it carries in one part of its genome. Researchers first identified it in Ontario in the spring of 2026, and it has been spreading steadily rather than exploding overnight. The picture that has emerged since then comes mainly from genomic surveillance — the routine sequencing of virus samples that lets scientists track which lineages are circulating — and from a study published in the Journal of Infection in October 2026 that examined the variant’s epidemiology and its behaviour in the laboratory.

1.1 A New Branch on the JN.1 Family Tree

According to the study published in the Journal of Infection, PJ.2.1 originated from a lineage called MC.10.1.7, which itself descends from JN.1, the lineage that circulated widely until around May 2025. That matters because it places PJ.2.1 in a familiar part of the virus family rather than in a wholly new one. JN.1 and its descendants have dominated global circulation for a long time, and most people will have some immune memory of them, either from infection or from vaccination. PJ.2.1 is therefore best understood as a new twig on a well-known branch, not as a tree of its own. The study, led by Markus Hoffmann and colleagues and titled “Epidemiology and virological characteristics of the emerging SARS-CoV-2 variant PJ.2.1”, was published online on October 24, 2026, in the Journal of Infection. Its findings are the main scientific source for what is known about the variant so far, and the rest of this article treats them as reported findings rather than as settled fact, because the variant is still new and the research base is still thin.

1.2 Why Scientists Call It a Saltation Variant

One word has followed PJ.2.1 through the coverage: saltation. The study describes it as a “novel saltation variant”, a term scientists use when a lineage appears with an unusually large number of mutations at once, rather than accumulating them gradually over many generations. In PJ.2.1’s case the changes are concentrated in the spike protein, the part of the virus that lets it enter human cells. A saltation event does not by itself mean a variant is more dangerous. It means the virus took a bigger evolutionary step than usual, and that step deserves a closer look. That is why health agencies have been watching PJ.2.1 even though it was first detected months ago: a lineage with many spike changes can behave differently from its parent, and the only way to know how is to study it. The spike changes are also the reason the variant has drawn comparisons with earlier moments in the pandemic, when heavily mutated lineages appeared suddenly and changed the course of circulation. The comparison is useful only up to a point, because this time the population has far more immunity, and the evidence so far points to a different outcome.

2. Where PJ.2.1 Has Been Found So Far

The geography of PJ.2.1 is now broad. From a single sample in Ontario in May, it has been reported in Canada, the United States, several European countries, Singapore, Australia, New Zealand and Israel. That spread took months, not weeks, and it followed the ordinary pathways of a respiratory virus in a world that has largely returned to normal travel. There is no single event that explains its movement. Instead, the pattern looks like steady, low-level transmission that genomic surveillance has gradually picked up, with Ontario — where sequencing is dense and reporting is detailed — giving the clearest picture of how fast its share of infections has grown.

2.1 From Ontario to New York and Beyond

After the first sample in Ontario on May 2, 2026, PJ.2.1 was found in other Canadian provinces, including Alberta, British Columbia and New Brunswick. The United States reported its first detection in New York City on June 30, 2026, and the variant was subsequently reported in several other states, including California, Arizona, New Jersey, Virginia, North Carolina, Missouri, Oklahoma, Colorado and Florida. Outside North America, detections have been reported in Singapore, Australia, New Zealand, Israel, France and Spain, and researchers in Spain have reported evidence of local transmission chains in several regions — a sign that the variant is not only arriving with travellers but spreading within communities. The list is almost certainly incomplete. Genomic sequencing covers only a fraction of infections, and many countries sequence far less than Canada or the United States, so the true distribution is likely wider than the confirmed detections suggest. That is a normal limitation of variant tracking, and it is one reason health agencies describe PJ.2.1 as spreading rather than contained.

2.2 The Ontario Numbers That Caught Attention

The figure that has done most to focus attention on PJ.2.1 comes from Public Health Ontario. According to genomic surveillance reports from the province, PJ.2.1 accounted for 25.2 percent of sequenced SARS-CoV-2 samples in the period from September 20 to October 17, 2026, up from 16.9 percent in the previous four weeks. A rise of that size over a single month is the kind of signal that surveillance systems are built to catch. It does not mean a quarter of all COVID cases in Ontario were PJ.2.1 — sequenced samples are a subset of all infections, and the subset is not random — but it does mean the variant’s share of the sequenced pool grew by roughly half in a month. That growth is consistent with the laboratory finding of a growth advantage, and it is the main reason the variant moved from a curiosity in May to a story in November. It is also worth noting what the Ontario numbers do not show: they do not show a surge in hospitalisations tied to the variant, and they do not show a new wave of severe disease. They show a lineage becoming more common, which is a different thing.

3. What the October Study Actually Found

The October 2026 study in the Journal of Infection is, for now, the most detailed scientific account of PJ.2.1. It combined epidemiology — where the variant was found and how fast its share grew — with laboratory work on how the virus behaves. The headline findings are twofold: the variant appears to bind more strongly to the human ACE2 receptor, the doorway the virus uses to enter cells, and it appears to have a growth advantage over other circulating strains. Neither finding is the same as saying it causes worse disease, and the researchers were careful to keep those questions separate. The study’s value is that it gives a mechanism for the spread that surveillance was already showing, and it gives health agencies something concrete to monitor.

3.1 Stronger Grip on the ACE2 Receptor

Early research on PJ.2.1 links its spread to stronger binding to the ACE2 receptor, the protein on the surface of human cells that the coronavirus uses to gain entry. The spike protein changes that define the variant appear to improve that binding, which would help the virus infect cells more efficiently and could explain why its share of sequenced samples has risen. This is a laboratory finding, and laboratory binding does not translate directly into real-world transmissibility — many factors, from immunity to behaviour to the season, shape how a variant spreads in a population. But it is a plausible mechanism, and it fits the epidemiological pattern. It also helps explain why scientists have paid attention to a variant that has not, so far, been linked to more severe illness: a virus that enters cells more easily can spread further even without becoming more harmful, and that alone is worth tracking.

3.2 A Growth Advantage, Not a Severity Signal

The study and the surveillance data agree on one point: PJ.2.1 appears to have a growth advantage over other circulating strains. In plain terms, when it competes with other lineages, its share of infections tends to rise. That is a statement about relative spread, not about absolute danger. A variant can outcompete its rivals simply by being slightly better at transmitting, and that is what the evidence suggests here. What the study does not show is any sign that PJ.2.1 is more likely to put people in hospital or to cause death. As of November 8, 2026, there was insufficient evidence to suggest that infection with PJ.2.1 is more likely to lead to hospitalisation, severe complications or death than infection with earlier variants. That distinction — between a growth advantage and a severity signal — is the most important thing to carry away from the science so far, and it is the distinction that much of the coverage has tried to keep in view.

4. The Symptoms: Why a Cold-Like Illness Is Hard to Spot

If PJ.2.1 has a defining clinical feature, it is how ordinary it looks. The World Health Organization has said that the symptoms associated with the variant may resemble those of the common cold or seasonal flu, and that symptoms alone cannot reliably distinguish a PJ.2.1 infection from influenza or other respiratory illnesses. That is not a claim that the variant causes a distinctive new set of symptoms. It is the opposite: a warning that there is no distinctive set of symptoms to look for, and that anyone trying to diagnose themselves by how they feel is likely to be guessing. In a season when colds, flu and COVID circulate together, that warning matters, because it is an argument for testing rather than for self-diagnosis.

4.1 What the WHO Said on November 8

On November 8, 2026, the WHO was quoted as saying that the symptoms of COVID-19, influenza and other respiratory infections can overlap, and that diagnostic testing should continue because symptoms alone cannot reliably tell them apart. The organisation has said it is watching PJ.2.1 closely as it turns up in new countries, and it continues to track SARS-CoV-2 variants through its global monitoring programme. One point of confusion in the coverage is worth clearing up: the WHO’s July 2026 variant list did not include PJ.2.1 among its variants under monitoring or variants of interest, according to reports, and at least one outlet has described the variant as now being listed as under monitoring. The precise formal status is therefore not fully settled in the public reporting, and this article does not claim a formal WHO designation that the sources do not agree on. What is clear is that the WHO is aware of the variant, is watching its spread, and has spoken publicly about the difficulty of distinguishing its symptoms from those of other respiratory infections.

4.2 Who Is Most Likely to Be Detected With It

The October study also reported a demographic pattern: PJ.2.1 has been more frequently detected in older age groups, particularly in people aged 70 and over. That finding needs care. It does not mean older people are more likely to catch the variant, and it does not mean the variant targets older people. Older people are more likely to be tested, more likely to seek care, and more likely to have their samples sequenced, so a detection pattern can reflect who gets tested as much as who gets infected. It is also possible that the pattern reflects real differences in exposure or susceptibility, but the study does not settle that question. What the finding does usefully do is point to the group that health systems already watch most closely in any respiratory season. If PJ.2.1 were to become more common, the people most likely to be affected in the first instance would be the same people who are most vulnerable to COVID and flu in any year, and that is a reason for surveillance to keep watching the age breakdown as well as the overall share.

5. Is PJ.2.1 More Dangerous Than Earlier Variants?

This is the question most readers will ask first, and it is the one the evidence answers most clearly — with a qualified no. There is currently no evidence that PJ.2.1 causes more severe illness than earlier variants, and experts quoted in the coverage have said the same. That is not the same as proof that it cannot cause severe illness, and it is not a promise about what will happen as it spreads further. It is a statement about what has been observed so far: a variant that is spreading, that has been studied in the laboratory, and that has not produced a signal of greater severity. The qualification matters, because the variant is still new, the number of cases is still relatively small, and severity can take time to show up in the data. But the direction of the evidence so far is reassuring rather than alarming.

5.1 What the Evidence Says About Severity

The case for reassurance rests on several strands. First, the October study found a growth advantage and stronger receptor binding, but no indication of a change in the virus’s ability to cause severe disease. Second, surveillance in Ontario and elsewhere has shown the variant’s share rising without a corresponding signal of increased hospitalisations tied to it. Third, the WHO’s public statements have focused on the difficulty of distinguishing symptoms, not on any warning of greater severity. And fourth, experts quoted in recent coverage have said there is no evidence at present that PJ.2.1 causes more severe illness than earlier variants, while recommending continued monitoring and precautions. None of this rules out a change in the picture, and none of it means the variant should be ignored. It means the risk, as currently understood, is the risk of a virus that spreads well in a population that already has substantial immunity, not the risk of a virus that has become markedly more harmful.

5.2 What Is Still Unknown

A great deal remains unknown, and it is worth listing it plainly. It is not yet clear how large PJ.2.1’s growth advantage really is, because the surveillance data covers only a few months and a limited number of countries. It is not yet clear whether the variant’s share will keep rising, plateau, or be overtaken by another lineage, as has happened repeatedly in the pandemic. It is not yet clear how well current vaccines protect against infection with PJ.2.1 specifically, as opposed to severe disease, because the variant is new and the relevant studies take time. It is not yet clear whether the age pattern — more frequent detection in people over 70 — reflects testing, exposure or biology. And it is not yet clear how the variant will behave in the northern hemisphere winter, when respiratory viruses typically spread more easily and health systems are under the most pressure. Each of those questions has an answer that will emerge over the coming weeks and months, and none of them can be answered responsibly from the evidence available today.

6. How Health Agencies Are Responding

The response to PJ.2.1 so far has been measured, and deliberately so. There have been no travel bans, no new restrictions and no emergency declarations tied to the variant. Instead, the response has been the ordinary machinery of variant tracking: sequencing, monitoring, testing and public communication. That is the appropriate response to a variant that is spreading but has not shown greater severity, and it is the response that health agencies have used for most new lineages since the emergency phase of the pandemic ended. The WHO’s emphasis on testing is the most concrete part of that response, because testing is what turns a cold-like illness into a known infection and what lets surveillance systems keep tracking the variant’s share.

6.1 Monitoring, Testing and Genomic Surveillance

Genomic surveillance is the backbone of the response. In Ontario, Public Health Ontario’s sequencing programme produced the numbers that brought PJ.2.1 to wider attention, and similar programmes in other countries are tracking its spread. The WHO has stressed that diagnostic testing should continue, precisely because the variant’s symptoms overlap with those of flu and other respiratory infections. Without testing, a PJ.2.1 infection looks like any other winter cold, and the variant’s spread becomes invisible. With testing, health agencies can see whether its share is still rising, whether it is appearing in new countries, and whether any severity signal emerges. That is why the WHO’s November 8 message was framed as it was: not as an alarm, but as a reminder that the tools for tracking the virus still matter, and that symptoms alone are not a substitute for them.

6.2 Where It Has Not Been Found Yet

The map of PJ.2.1 is not yet global. India, for example, has genomic surveillance through its INSACOG network, but reports do not confirm detection of this variant in the country so far. No cases have been reported in Kuwait or the wider Gulf region so far, according to recent coverage, although variants that spread this widely often reach more countries over time. Those absences should not be read as proof that the variant is absent — sequencing coverage varies enormously, and a variant can circulate undetected in places that sequence little. But they do show that PJ.2.1’s spread, while broad, is not yet universal, and that there are still regions where it has not been confirmed. That matters for two reasons. First, it gives health systems in those regions time to prepare. Second, it is a reminder that the variant’s story is still being written, and that the map will look different in a month’s time.

7. What This Means for Vaccines and Everyday Precautions

For most people, the practical implications of PJ.2.1 are modest. The variant’s spike changes are the reason scientists are watching it, and spike changes are also the reason vaccine protection against infection can wane as a virus evolves. But protection against severe disease has proved far more durable than protection against infection throughout the pandemic, and there is no evidence so far that PJ.2.1 changes that pattern. The advice from health agencies has been correspondingly modest: keep monitoring, keep testing, and take the ordinary precautions that apply to any respiratory season. That is not a call for alarm, and it is not a call for complacency. It is a call for the same steady approach that has governed the last two years of COVID management.

7.1 Vaccines and the Spike Changes

Early research links PJ.2.1’s spread to stronger binding to the ACE2 receptor, not to escaping vaccine protection, according to coverage of the October study. That distinction is important. A variant that binds better can spread more easily without necessarily evading the immune response that vaccines and prior infections have built up. The spike mutations that define PJ.2.1 are numerous, and numerous spike mutations can in principle reduce how well antibodies recognise the virus, but there is no evidence so far that this variant escapes vaccine protection in a meaningful way. The question will be studied, as it is for every new lineage, and the answer will come from laboratory studies of antibody neutralisation and from real-world data on vaccine effectiveness. Until then, the reasonable reading of the evidence is that existing vaccines should continue to protect against severe disease from PJ.2.1, as they have against other recent lineages, while protection against mild infection may be less complete. That reading is provisional, and it should be treated as such.

7.2 Practical Steps While the Picture Clears

The practical steps are familiar, and they are the same ones that apply to any winter respiratory season. People with cold or flu-like symptoms who want to know whether they have COVID should test rather than guess, because the WHO has said symptoms alone cannot reliably distinguish the infections. People who are older or have underlying health conditions — the group in which PJ.2.1 has been most frequently detected — should take particular care, and should seek medical advice promptly if symptoms worsen. Staying home while ill, ventilating indoor spaces, and keeping up with recommended vaccinations remain the basic measures. None of these steps is new, and none of them is specific to PJ.2.1. That is the point: the variant does not, on current evidence, call for new measures. It calls for the existing ones to be used properly, and for surveillance to continue so that the picture can be updated as more data arrives.

8. The Bottom Line

PJ.2.1 is a real development, and it deserves attention, but it does not deserve panic. A new lineage of SARS-CoV-2, first detected in Ontario in May 2026, has spread to the United States, Europe, Asia and Oceania, and now accounts for about a quarter of sequenced samples in Ontario. A study published in the Journal of Infection in October 2026 found that it binds more strongly to the ACE2 receptor and has a growth advantage over other circulating strains. The WHO has warned that its symptoms can resemble a cold or flu, and has stressed that testing, not guesswork, is the way to tell the difference. And through all of that, there is no evidence that it causes more severe illness than earlier variants. That is the balance of the evidence as it stands in mid-November 2026: a variant that spreads well, that is being watched closely, and that has not shown itself to be more dangerous.

8.1 What to Watch in the Coming Weeks

Several things will tell us more about PJ.2.1 in the coming weeks. The first is the Ontario sequencing data: if the variant’s share keeps rising, the growth advantage is real and sustained; if it plateaus, the advantage may have been overstated. The second is whether it is confirmed in countries where it has not yet been reported, including India and the Gulf states, which will show how far its spread has really gone. The third is whether any severity signal emerges as case numbers grow — the absence of such a signal so far is reassuring, but severity signals can lag behind spread. The fourth is the WHO’s formal classification: whether PJ.2.1 is added to a monitoring list, and what that says about how the organisation views it. And the fifth is the laboratory work on vaccines: whether antibodies from vaccination or prior infection neutralise the variant as effectively as they neutralise other recent lineages. Each of those will be reported as it happens, and each will refine the picture.

8.2 The Bottom Line

The bottom line is straightforward. PJ.2.1 is spreading, it is being monitored, and it has not shown signs of causing more severe disease. Its symptoms look like a cold, which makes testing more important, not less. Its growth advantage makes it worth watching, but a growth advantage is not a severity signal. The coming weeks will provide the answers to the questions that remain — how far it spreads, whether its share keeps rising, and whether the reassuring picture on severity holds. Until then, the sensible response is the one health agencies have already adopted: keep testing, keep sequencing, and keep the ordinary precautions in place.

Comments

comments